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Abstract. The combination of therapy and diagnostics in one process “theranostics” is a trend in a modern medicine, 
especially in oncology. Such an approach requires development and usage of multifunctional hybrid nanoparticles with a 
hierarchical structure. Numerical methods and mathematical models play a significant role in the design of the 
hierarchical nanoparticles and allow looking inside the nanoscale mechanisms of agent–cell interactions. The current 
position of in silico approach in biomedicine and oncology is discussed. The review of the molecular level in silico 
studies in oncology, which are using the direct models, is presented. 
THERANOSTICS AND THE HIERARCHICAL NANOPARTICLES 
Recently, more and more researchers have noted that to treat serious illnesses such as cancer an interdisciplinary 
approach is required [1, 2]. It is necessary to involve specialists from various non-traditional fields, including 
physicists and mathematicians. Mathematical models and computer simulations allow both to deeply analyze 
experimental and statistical data and to obtain additional qualitative and quantitative data from the numerical 
experiments at almost any time and spatial scales. 
Combining therapy and diagnostics into a united procedure is a trend in modern biomedicine and, especially, in 
oncology. A new hybrid term that is used to define this complex approach is “theranostics”, namely meaning 
therapy plus diagnostics. Targeted cancer therapy and imaging using hybrid multifunctional nanoparticles (NP) with 
core-shell structure proposed by Li et al. [3] is a vivid example of the theranostic approach. The key role in this case 
is played by the hierarchical nanoparticles. The hierarchy includes three functional levels. The first (most inner) 
level is a core made of ferromagnetic metal supra-particles. Magnetic property provides nano-agent with many 
functions as ability being concentrated within the necessary tissue area using external magnetic field [4], ability to 
enhance contrast in magnetic resonance imaging (MRI) of tumors, and also allows using magnetic separation during 
preparation. The second level is a shell made of Ni-Al layered double hydroxide (LDH) nanosheets hosting drug 
molecules. LDH is ceramics having layered nanostructure with host-guest architecture, where staked positively 
charged nanosheets of metal hydroxide are “glued” together by guest water molecules and charge balancing anions. 
The third (outer) level is modified anticancer drug doxorubicin having deprotonated carboxylic group (DOX-COO–) 
as a guest anion between LDH nanosheets. The formation of LDH-drug nanohybrid is possible via anion-exchange 
intercalation mechanism due to competitive ion adsorption onto LDH nanosheets. 
The surface of hierarchical NP was functionalized by (iminodiacetic acid)-modified folate via the chelating 
interaction, enabling the NP to target HeLa cells. After the cellular uptake of the hierarchical NP by cancerous cell, 
modified DOX-COO–, being in the acidic cytoplasm, takes the cationic form. Further, due to electrostatic repulsion, 
the cationic therapeutic agent releases from the interlayer space of LDH. 
Not only doxorubicin but many other anticancer drugs can be intercalated within hydrated gallery space of LDH, 
forming stable nanohybrid. The nanohybrids containing camptothecin (CPT) [5], 10-hydroxycamptothecin (HCPT) 
[6], 5-fluorouracil (5-FU) [7, 8], methotrexate (MTX) [9–12], doxifluridine (DFUR) [13] and podophyllotoxin 
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(PPT) [14] are among experimentally synthesized ones. Moreover, the formation of stable LDH-based nanohybrids 
with intercalated antibiotics, vitamins, liposomes, genes, amino acids, antioxidants and many other bio-molecules 
was reported in many publications. 
The theranostic anticancer system composed of a multifunctional endoscope and hierarchical nanoparticles was 
proposed by Lee et al. [15]. The hierarchical NP with core-shell structure had a gold nanorod as the core, and the 
double shell. The inner shell was made of mesoporous silica with fluorescent dyes, photodynamic compounds and 
the doxorubicin embedded. The second layer of the shell, composed of thermosensitive poly-(N-iso-propyl-acryl-
amid), plays the role of “crust”, preventing DOX release from the NP. The surface of NP was functionalized with 
specific anti-bodies Cetuximab, which allow targeting of HT-29 cell line of colon cancer. These anti-bodies interact 
with the receptors of the epidermal growth factor, which are abnormally high expressed on the colon cancer cell 
membrane. During endoscopic examination, fluorescent dye (rhodamine B) allows revealing cancerous areas, which 
further undergo an irradiation of red (670 nm) and near infrared (808 nm) lasers. Under the lasers treatment 
hierarchical NPs directly generate reactive oxygen species (photodynamic therapy), warms up cancer cells 
(photoinduced hyperthermia) and releases doxorubicin in a controlled way after the outer polymeric shell 
thermodestruction. 
The multifunctional NPs on a base of magnetic iron oxide with controlled release of gemcitabine (GEM) for 
targeted therapy and magnetic resonance imaging (MRI) of pancreatic cancer is also a vivid example of the 
theranostics approach in oncology [16]. After the internalization of such a nanoparticle in the endosome or lysosome 
a tetrapeptide GFLG linker (degradable under the acidic pH and in the presence of cathepsin B), which covalently 
binds core with therapeutic agent, breaks up, releasing free GEM into the cancer cell. The rest part of the particle 
acts as MRI contrast agent. 
Summarizing, the further progress in the theranostic approach requires the development of multifunctional 
hierarchical nanoparticles (MHNP). 
IN SILICO APPROACH IN THE PROBLEMS OF THE ONCOLOGY 
In block-scheme the MHNP development process may be represented as a sequence of design and synthesis, as 
well as in vitro, in vivo testing and clinical trials. In vitro studies are performed with cell models, in vivo studies 
utilize animal (mammalian) models. Studies “in silico”, meaning literally “on silicon chips”, deal with numerical 
models (Fig. 1). 
FIGURE 1. (a) In silico approach in the oncology and biomedicine in the broad sense of this term. (b) A rough scheme  
of the MHNP development sequence. Orange arrow shows in silico block position accordingly to most common meaning  
in oncology, but actual position is aside, having connections with almost all other blocks (explanation is in the text) 
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Traditionally, in silico approach in oncology combines the information analysis methods as statistical methods, 
data-base processing, machine learning, genetic and evolutional algorithms, which are usually used at the computer-
aided drug design stage (Fig. 1a, first block). However, the “in silico” term is wider and can also “absorb” all 
numerical methods, including direct modeling, based on mathematical physics: particle dynamics methods as 
movable cellular automata, all-atom and coarse-grained molecular dynamics, kinetic Monte-Carlo and molecular 
docking as well as quantum mechanics calculations, finite element and finite differences methods, etc. (Fig. 1a, 
second block). Moreover, in silico experiments may assist not only nano-agent design but, for example, its synthesis, 
simulating reactions and estimating optimal synthesis parameters, or estimating energy characteristics of organic-
inorganic nanohybrid formation, showing the conditions of nanocomplex stability (Fig. 1b, yellow arrow). In 
particular, estimating from the in silico experiments Gibbs free energy of DOX molecule binding with Fe-Ag 
surfaces, the conditions of the drug release from nanocomposite can be found, which is quite important for the 
development and fabrication of biodegradable implants encapsulated with anticancer therapeutics [17]. The same is 
true for in vitro testing, where in silico approach, for instance, may shed some light on the molecular level 
interaction of MHNP with the cell membrane and membrane proteins, mechanisms of endosome formation, lipid 
bilayer disruption etc. (Fig. 1b, green arrow). 
The use of computer technologies in oncology studies has been developing rapidly over the past decades due to 
many reasons, including the development of computational techniques, and the increase in supercomputer 
performance [1, 2, 18, 19]. The first block methods, roughly called here “data analysis”, are widely used in oncology 
[20–22]. Direct models at the molecular level for the anticancer nano-agent development, illustrating second block 
methods, are considered in the next section. 
MOLECULAR LEVEL IN SILICO STUDIES IN ONCOLOGY 
In silico investigation on DNA nanotubes as drug delivery vehicle for four anticancer therapeutics agents was 
conducted by Liang et al. using the molecular dynamics (MD) modeling [23]. In the study doxorubicin (DOX), 
daunorubicin (ADR), taxol (TAX) and vinblastine (VIN) were considered as model drug molecules. These 
anticancer agents are hydrophobic molecules and possess poor water solubility, moreover, they are non-selective 
and can exhibit a toxic effect to the normal cells. Therefore, the development of the hybrid nanoparticles for 
selective/targeted delivery and the controlled release of such hydrophobic drugs are quite important. The current 
progress in DNA-nanotechnologies provides the unprecedented opportunities for the manufacture of DNA 
nanostructures with precise geometry and universal functionality, in particular, self-assembled DNA nanotubes 
(DNTs), which are inherently non-toxic and biocompatible. In addition, they can be labeled with folic acid to target 
specific receptors in the cancer cell membrane [24]. 
The results of the MD simulation series demonstrated that the formation of multimolecular nanocomplexes of 
DNT oligomers with each of drugs molecules considered is possible. The model DNA nanotubes were built from 
four, six and eight double strands DNA with the poly-(adenine-thymine)20 sequence. The analysis of the molecular 
level absorption mechanism of anticancer drugs by DNT showed that both electrostatic interaction and van der 
Waals forces play the role in the nanocomplex formation, but the contribution of the second ones is higher. Liang 
and co-workers found that this reduces the aggregation of anticancer drugs in water and at the same time increases 
the stability of the DNA-nanotubes themselves. 
Another drug delivery vehicle based on the carbon nanotube was investigated using in silico approach by 
Mousavi et al. [25]. The all-atom level molecular dynamics simulations of the hierarchical NP translocation through 
cell membrane were performed. Nanoparticle has host-guest structure, where single-walled carbon nanotube (CNT) 
with opened ends contained anticancer drug paclitaxelum (PTX). The core of the PTX molecule is polar. Four 
steered MD simulations were conducted with different values of the velocity constant. The orientation of the CNT 
was constrained to be perpendicular to the lipid bilayer plane during pulling process. The PTX molecule was 
initially placed near the second CNT end, which is more distant from the membrane. The greatest resistance to 
penetration was observed when the PTX@CNT nanocomplex was passing through the lipid tail region, which is 
associated with the hydrophobic interactions between the lipophilic groups of the lipids and the outer surface of 
CNT. It was shown that during PTX@CNT translocation several lipids and the water molecules were captured 
inside nanotube. The amount of lipids entering the CNT inner space decreases with increasing the speed of the NP 
translocation. Furthermore, the amount of lipids that are completely removed out from the membrane by the NPs 
also decreases. It was noted that for the retention of the PTX molecule inside the CNT, an especial role is played by 
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van der Waals forces between PTX and the inner wall of CNTs, as well as by hydrogen bonds formation between 
PTX and the water molecules, which were trapped inside the nanotube. 
Using single-walled CNT as a nanocarrier for another anticancer therapeutic agent—vinblastine was investigated 
in silico utilizing several theoretical tools such as molecular dynamics, quantum mechanics and Monte-Carlo 
methods, aiming to analyze the stability and conformation of the drug molecule inserted into CNT [26]. 
Aronda and co-authors conducted a comprehensive in silico study, including molecular docking followed by the 
molecular dynamics simulations and the post-dynamic analysis to understand whether the nelfinavir (NFV) and 
eight other HIV-1 protease inhibitors could act as anticancer drug [27]. It was previously hypothesized that the 
known anticancer activity of NFV is due to its inhibitory effect on heat shock protein 90 (Hsp90), which is a 
promising target for anticancer therapy. Thus, to justify the assumption and to understand possible mechanism, the 
free energy of nine HIV-1 protease inhibitors binding with Hsp90 were estimated. The obtained results showed that 
all of nine molecules exhibit affinity to Hsp90, moreover, the binding of NFV with Hsp90 has the largest gain in 
energy (ǻG = –38.5 kJ/mol) in comparison with other protease inhibitors considered: the binding affinity of 
indinavir, saquinavir and ritonavir with protein are characterized by free energy change ǻG = –37.7, –36.0 and  
–35.6 kJ/mol, respectively. It means that NFV and eight other HIV-1 protease inhibitors may possess the same 
action with respect of heat shock protein of the cancer cell. It was also found that the most dominant role in the 
binding of the drug is played by the hydrophobic interactions, especially with Val534 and Met602 protein residues. 
Two-dimensional carbon nanomaterials such as pristine graphene nanosheets, graphene oxide (GO), PEGylated 
GO (functionalized with polyethylene glycol) [28], as well as nitrogen-doped graphene [29] are also attracted 
attention as the prominent base for the development of the anticancer drug delivery system. Wang et al., using all-
atom MD, found that the binding of finite graphene nanosheets with anticancer drugs CE6, DOX, MTX and SN38 is 
favorable when the drug molecule and the nanosheet have comparable sizes, since in this case the deformation of 
graphene nanosheet is minimized [28]. The estimates of the average binding energy vary from 40 to 290 kJ/mol. It 
was also found that the nanosheet boundaries restrict the movement of the drug molecules adsorbed. Besides, the 
PEGylated GO nanosheets bind the drug molecules more strongly as compared to pristine one. Azizi and Ebrahimi 
conducted in silico study of pristine graphene nanosheet and N-doped one binding with anticancer drug paclitaxel 
(PTX), using MD [29]. It was demonstrated that content of nitrogen atoms influences adsorption of PTX at the 
nanosheet. Moreover, the optimal value of N atoms concentration in N-doped graphene nanosheet was estimated as 
6.8%. 
In this context, it is also pertinent to mention our in silico study, which is not directly associated with the 
oncology, but devoted to the formation of organic-inorganic nanohybrid based on LDH, which can be used for the 
development of the drug delivery system [30]. Using all-atom level MD models, the interaction of organic anions 
with the single nanosheet of Mg/Al-LDH was characterized. The typical configurations of “soft-matter” organic 
anions on the LDH surface in the adsorbed state were found and most common binding sites. Quantitative 
estimations for non-covalent bonds formation were obtained. Using constant velocity steered MD technique, the free 
energies of adsorption for aspartic and glutamic amino acid anions, bicarbonate-anion and chlorine on the LDH 
nanosheet were evaluated, characterizing the competitive adsorption sequence for modeled anions: 
Cl– < HCO3– < Asp– | Glu–, 
where in the estimates of the free energy wells depths for the anionic amino acids residues are quite large—about 
50 kJ/mol. Strong interaction energy provides the formation of hybrid multimolecular complexes. The outcome for 
the theranostics could be the possibility of non-covalent functionalization of the LDH-based hierarchical NPs with 
receptor binding peptides, contained in the structure the anionic amino acid residues Asp– and Glu–. The obtained 
competitive adsorption series means that no one of extracellular anions (Cl– and HCO3–) can release Asp– or Glu– 
amino acids from nanoparticle surface before cellular uptake of the NP. 
SUMMARY 
A new stage of in silico approach for solution of oncology problems based on development of direct modeling 
(and not just the information analysis) started. Direct modeling provides the understanding of the mechanisms at the 
nanoscale level that cannot be investigated employing the known methods. 
Further development of numerical modeling methods and computational technologies will allow solving 
multiscale problems, providing the possibility to predict the biomedical action of drugs, including adverse side 
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effects, directly based on their structure. This would allow rapid design and production of the novel theranostic 
nano-agents for the treatment of complex diseases, such as cancer. 
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